Controlling Health Care Costs Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier? Issue Briefs / Oct 05, 2017
Controlling Health Care Costs The Case for Drug-Pricing Reform — The Cost of Inaction blog / May 26, 2021
Controlling Health Care Costs External Reference Pricing: The Drug-Pricing Reform America Needs? Issue Briefs / May 27, 2021
Controlling Health Care Costs How Federal Drug-Pricing Proposals Could Affect Medicaid blog / Aug 19, 2021
Controlling Health Care Costs Reducing Medicaid Prescription Drug Costs While Maintaining Beneficiary Access: MACPAC Recommendations for Accelerated-Approval Drugs blog / Aug 18, 2021
Controlling Health Care Costs Reducing Spending on Prescription Drugs with Limited Clinical Evidence Blog / Apr 08, 2021
Controlling Health Care Costs Prospects for Drug-Pricing Reform Under a Biden–Harris Administration Blog / Mar 23, 2021
Controlling Health Care Costs Addressing Medicare Solvency Will Require Both Revenue and Spending Changes Blog / Jan 28, 2021
Controlling Health Care Costs Any Medicare Solvency Effort Must Include Advancing Health Equity Blog / Jan 28, 2021
Controlling Health Care Costs Options for Extending Medicare’s Trust Fund: The Commonwealth Fund Solvency Series Blog / Jan 28, 2021
Controlling Health Care Costs The Trump Administration’s Latest Prescription Drug Rulemaking and Options for President-elect Biden Blog / Dec 03, 2020
Controlling Health Care Costs Striking the Right Balance Between Lowering U.S. Prescription Drug Prices and Preserving Incentives for Innovation Journal Article / Dec 02, 2020
Controlling Health Care Costs Health Care in the 2020 Presidential Election: Prescription Drugs Blog / Oct 07, 2020
Controlling Health Care Costs Getting to Lower Prescription Drug Prices: The Key Drivers of Costs and What Policymakers Can Do to Address Them Fund Reports / Oct 01, 2020
Controlling Health Care Costs Not So Sweet: Insulin Affordability over Time Issue Briefs / Sep 25, 2020